JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gasior, M.
Right arrow Articles by Witkin, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gasior, M.
Right arrow Articles by Witkin, J. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*COCAINE
Medline Plus Health Information
*Seizures

Vol. 290, Issue 3, 1148-1156, September 1999

Preclinical Evaluation of Newly Approved and Potential Antiepileptic Drugs Against Cocaine-Induced Seizures1

Maciej Gasior2, Jesse T. Ungard and Jeffrey M. Witkin

Drug Development Group, Behavioral Neuroscience Branch, Addiction Research Center, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland

Seizures and status epilepticus are among the neurological complications of cocaine overdose in humans. The aim of the present study was to evaluate the protective effectiveness and therapeutic index (separation between anticonvulsive and side effect profiles) of 14 newly approved and potential antiepileptic drugs using a murine model of acute cocaine toxicity and the inverted-screen test for behavioral side effect testing. Cocaine (75 mg/kg i.p.) produces clonic seizures (~90% of mice), and conventional antiepileptic drugs have been reported to be either ineffective or only effective at doses producing significant sedative/ataxic effects. Clobazam, flunarizine, lamotrigine, topiramate, and zonisamide were ineffective against seizures up to doses producing significant motor impairment. In contrast, felbamate, gabapentin, loreclezole, losigamone, progabide, remacemide, stiripentol, tiagabine, and vigabatrin produced dose-dependent protection against cocaine-induced convulsions with varied separations between their anticonvulsant and side effect profiles: the protective index values (toxic TD50/anticonvulsive ED50) ranged from 1.26 (felbamate) to 7.67 (loreclezole), and gabapentin had the highest (protective index >152). Thus, several drugs were identified with greater protective efficacy and reduced motor impairment compared with classic antiepileptic drugs. Based on the proposed mechanism of action of these new anticonvulsants, it is noteworthy that 1) drugs that enhance gamma -aminobutyric acid-mediated neuronal inhibition in a manner distinct from barbiturates and benzodiazepines offer the best protective/behavioral side effect profiles, and 2) functional antagonists of Na+ and Ca2+ channels are generally ineffective. Overall, this study provides the first description of the effectiveness of new antiepileptic drugs against experimentally induced cocaine seizures and points to several drugs that deserve clinical scrutiny for this indication.


0022-3565/99/2903-1148$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by U.S. Government



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
J. M. Witkin, D. Dijkstra, B. Levant, H. C. Akunne, A. Zapata, S. Peters, H. E. Shannon, and M. Gasior
Protection against Cocaine Toxicity in Mice by the Dopamine D3/D2 Agonist R-(+)-trans-3,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907]
J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 957 - 964.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
F. Crestani, K. Löw, R. Keist, M.-J. Mandelli, H. Möhler, and U. Rudolph
Molecular Targets for the Myorelaxant Action of Diazepam
Mol. Pharmacol., March 1, 2001; 59(3): 442 - 445.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Gasior, J. T. Ungard, and J. M. Witkin
Chlormethiazole: Effectiveness against Toxic Effects of Cocaine in Mice
J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 153 - 161.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.